Monaco Secures $50M Series B Investment Led By Benchmark With Founders Fund And Others

Monaco raised a $50M Series B led by Benchmark, with Founders Fund and Human Capital tripling down in the round, alongside participation from investors including Jason M. Lemkin, Mantis, Saga, Antifund, Menlo Ventures, Liquid2, A*, and Daft. The company said it gave Benchmark an early look at its upcoming GA release and secured the term sheet within hours, framing the product as a redefinition of sales software. Jack Altman is also joining the board as part of the new financing round. FOUNDER: Sam Blond & Brian Blond INVESTORS: Benchmark, Founders Fund, Human Capital, Jason M. Lemkin, Mantis, Saga, Antifund, Menlo Ventures, Liquid2 Ventures, A* & Daft ROUND: Series B AMOUNT: $50,000,000 HQ: San Francisco, California #VentureCapital #Monaco #SamBlond #BrianBlond #TradedVC

More Deals

View All

Colossal Biosciences In Talks For Funding Round Targeting $23 Billion ValuationColossal Biosciences, the de-extinction biotech startup known for its efforts to recreate the woolly mammoth and other extinct species, is reportedly in talks to raise new funding at a valuation of roughly $23 billion–$24 billion, according to Axios. The potential raise would mark a significant jump for the five-year-old company, with investors valuing not only its genetic-engineering programs but also its broader genomics, reproductive technology, conservation, and intellectual property platform. Colossal has begun generating revenue through conservation technology sales and technology spinouts, including Astromech, an AI-driven predictive modeling company, and Form Bio, a computational biology platform, expanding its value beyond de-extinction efforts. FOUNDERS: Ben Lamm & George Church TARGET VALUATION: $23,000,000,000 HQ: Dallas, Texas #VentureCapital #ColossalBiosciences #BenLamm #GeorgeChurch #TradedVC